Two Vaccines Against Ebola Have Successfully Passed Safety Test
The experimental vaccines against Ebola developed by GlaxoSmithKline and NewLink Genetics have been recognized as being safe by the results of tests taken in Liberia.
As part of the research, held under the auspices of the National Institute of Allergy and Infectious Diseases, injections of experimental drugs or placebo were made made for 600 volunteers.
At present the volunteers are recruited for the next phase of clinical trials, the launch of which is scheduled for the end of April. The organizers intend to select 1.5 thousand.healthy Liberia citizens for vaccine trials.
In total, during the epidemic hemorrhagic fever affected about 24 thousand citizevts of West Africa, among which more than 10 thousand died. Infections have been spread in the areas of Guinea, Liberia and Sierra Leone most.
- GlaxoSmithKline Has Successfully Tested A Vaccine Against Shingles
- Speedly Diagnosis Of Ebola For In-The-Fields Conditions Has Become Real
- New Anti-Ebola Medication Tests Continue